Latest News About Microangiopathic Hemolytic Anemia

Here’s the latest overview based on available up-to-date sources.

• MAHA refers to a group of disorders causing intravascular red cell fragmentation, with conditions like TTP/HUS and other thrombotic microangiopathies. Recent reviews emphasize its broad etiologies, including autoimmune, infectious, malignant, and iatrogenic causes, and highlight the importance of prompt diagnostic workup and targeted therapy.[1][4]
• Key diagnostic hallmarks include schistocytes on the blood smear, elevated LDH, reduced haptoglobin, thrombocytopenia, and evidence of organ involvement (kidney, CNS) in many TMAs. Therapies vary by cause but often involve plasma exchange for classic TTP and disease-specific strategies for atypical HUS or secondary MAHA.[6][7][1]
• In cancer-associated MAHA and other secondary MAHAs, treatment focuses on the underlying malignancy; plasmapheresis may be less beneficial, and prognosis tends to be more dependent on cancer control and performance status.[3][9]
• Recent reviews and case reports underscore evolving approaches, including complement-directed therapies for complement-mediated MAHAs and the need to distinguish MAHA from other anemia etiologies (e.g., megaloblastic anemia or DIC) to avoid unnecessary plasma exchange.[5][7][10]

Illustration: A typical diagnostic pathway

• Suspect MAHA with anemia and thrombocytopenia; check blood smear for schistocytes.
• Order LDH, haptoglobin, bilirubin, reticulocyte count, and coagulation studies to differentiate microangiopathies from DIC or immune hemolysis.
• Initiate urgent management based on likely cause: plasma exchange for suspected TTP; treat underlying disease in secondary MAHA; consider complement inhibitors if complement-mediated MAHA is suspected.
• Monitor organ function (renal, neurologic) and adjust therapy as test results clarify the diagnosis.

If you’d like, I can pull the most recent primary sources or craft a succinct, cited brief for Montréal-based clinical teams, and I can also summarize how MAHA presents differently in cancer-related cases versus autoimmune TTP.